VNRX 0.73 VolitionRx Limited
| Range: | 0.43-1.23 | Vol Avg: | 139015 | Last Div: | 0 | Changes: | 0 |
| Beta: | 1.1 | Cap: | 0.07B | Currency: | USD | Exchange: | AMEX |
| Sector: | Healthcare | IPO: | Fri Mar 02 2012 | Empoloyees: | 101 | ||
| CUSIP: | 928661107 | CIK: | 0000093314 | ISIN: | US9286611077 | Country: | US |
| CEO: | Mr. Cameron Reynolds MBA | Website: | https://www.volition.com | ||||
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow